 Drugs for Neglected Diseases Initiative

The Drugs for Neglected Diseases "initiative" (DND"i") is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness (human African trypanosomiasis, HAT), Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, and hepatitis C. DND"i"'s malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.Led by Executive Director Bernard Pécoul, DND"i" is headquartered in Geneva, Switzerland, with offices in Brazil, the Democratic Republic of Congo, India, Japan, Kenya, Malaysia, South Africa, and an affiliate in the United States.